Neurocrine Biosciences Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +14.2% | +6.8% | -4.8% | +7.0% | +5.2% | -0.8% | +5.5% | +9.7% | +8.6% | +5.9% | +9.2% | |
| – | -2.6% | +11.9% | -7.2% | +12.4% | -8.1% | -5.0% | +6.8% | +23.4% | +16.9% | -3.4% | -32.8% | |
| – | -14.5% | +57.8% | -64.7% | +149.9% | -33.3% | -16.7% | +36.0% | +28.9% | +109.6% | -62.6% | +24.7% | |
| – | -5.8% | +17.4% | -14.2% | +18.2% | -12.4% | -12.3% | +3.4% | +14.3% | +32.8% | -11.1% | -70.4% | |
| – | +5.1% | +2.6% | +3.9% | +2.8% | -0.4% | +7.7% | +15.4% | +22.2% | -5.7% | +11.8% | +15.5% | |
| – | +33.0% | -2.9% | +14.2% | +7.8% | +25.3% | +3.0% | -3.7% | +21.8% | -0.4% | -6.5% | +61.6% | |
| – | – | – | – | +7.0% | -39.3% | – | – | – | – | – | – | |
| – | +1.7% | -3.4% | -2.3% | +3.0% | +5.8% | -0.3% | +2.2% | -4.0% | – | – | – | |
| – | +20.5% | +6.6% | -26.7% | +2.6% | +38.3% | +2.0% | +3.8% | +5.6% | +9.2% | +8.7% | +11.1% | |
| – | -5.3% | +8.9% | -44.1% | +7.8% | +18.2% | +3.0% | +4.5% | +16.8% | +16.5% | +11.9% | +5.1% | |
| – | -9.4% | +52.3% | -86.3% | -1.7% | – | – | – | – | – | – | – | |
| – | +42.1% | -34.5% | +22.8% | -10.7% | +4.4% | +10.1% | -4.9% | +14.6% | -12.5% | +14.4% | +18.3% | |
| – | +11.5% | +6.9% | +5.2% | +8.4% | -4.8% | -2.1% | +6.3% | +11.5% | +8.3% | +4.7% | +8.4% | |
| – | – | – | – | – | -64.0% | -118.2% | – | +247.9% | +52.3% | +31.7% | +22.8% | |
| – | +1.2% | +1.3% | +0.3% | +0.4% | -1.3% | -0.4% | -1.5% | +1.5% | +0.0% | +0.9% | +0.8% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.